<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20260924071176N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2026-09-29</date_registration>
      <primary_sponsor>Evercare Hospital Lahore</primary_sponsor>
      <public_title>Intraoperative Ketamine vs Magnesium for Acute Postoperative Pain in Unilateral Knee Replacement Surgery during regional anesthesia: A randomized Controlled Trial</public_title>
      <acronym></acronym>
      <scientific_title>Intraoperative Ketamine vs Magnesium for Acute Postoperative Pain in Unilateral Knee Replacement Surgery during regional anesthesia: A randomized Controlled Trial</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2025-05-30</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>64</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/93645</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Eligible participants will be randomly allocated to one of two parallel groups (ketamine or magnesium) using a simple randomization method by lottery. The individual participant will be the unit of randomization. The random allocation sequence will be generated using the lottery method, with participants assigned to either the ketamine or magnesium group according to the selected allocation. Participants and the outcome assessor will remain unaware of group allocation throughout the study, Blinding description: Participants and the outcome assessor will be blinded to group allocation. Participants will not be informed whether they receive ketamine or magnesium. The outcome assessor will be unaware of the treatment group during postoperative outcome assessment. The treating anesthesia team will know the group allocation for administration of the study drug.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Acute postoperative pain after unilateral knee replacement surgery.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Ketamine group. Participants will receive intraoperative ketamine infusion in addition to standardized perioperative anesthetic and analgesic management. Ketamine will be administered as an intravenous bolus of 0.5 mg/kg followed by a continuous intravenous infusion at 2–5 mcg/kg/min. The infusion will be started before surgical incision and continued throughout the intraoperative period. Intervention 2: Intervention group: Magnesium group. Participants will receive intraoperative magnesium sulfate infusion in addition to standardized perioperative anesthetic and analgesic management. Magnesium sulfate will be administered intravenously at a dose of 40 mg/kg over 15 minutes before induction of anesthesia, followed by a continuous intravenous infusion of 15 mg/kg during the surgical procedure until skin closure.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>No - There is not a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for not sharing IPD is Ethical concerns</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Dr. Asma Bhatti</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>D1 Commercial , NECHS Block D 1 Nespak Housing Society Lahore</address>
        <city>Lahore</city>
        <country1>Pakistan</country1>
        <zip>54700</zip>
        <telephone>+92 42 111 227 333</telephone>
        <email>drasmabhatti03@gmail.com</email>
        <affiliation>Evercare Hospital Lahore</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Dr. Ateeq ur Rehman Ghafoor</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>D1 Commercial , NECHS Block D 1 Nespak Housing Society</address>
        <city>Lahore</city>
        <country1>Pakistan</country1>
        <zip>54700</zip>
        <telephone>+92 333 4636106</telephone>
        <email>ateeq.rehman@evercare.pk</email>
        <affiliation>Evercare Hospital Lahore</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Pakistan</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Patients aged &gt;18 years
Patients scheduled for elective unilateral total knee replacement surgery
Both male and female patients
Patients classified as ASA physical status I–III
Patients able to provide informed consent before surgery
Patients able to understand and report their pain score</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Allergy or contraindication to ketamine or magnesium
Pre-existing chronic pain conditions (fibromyalgia, neuropathic pain)
Current opioid dependence or substance abuse history (alcohol, illicit drugs)
Use of medications effecting NMDA receptors (SSRIs, SNRIs, antipsychotics) and if already on calcium channel blockers.
Neurological disorders (epilepsy, h/o seizures, increases ICP)
Pregnant or breastfeeding
Uncontrolled cardiovascular disease (arrythmias, ischemic heart disease)
Severe hepatic or renal impairment (liver cirrhosis, creatinine clearance &lt;30 mL/min)</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>G89.18</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Other acute postprocedural pain</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Ketamine group. Participants will receive intraoperative ketamine infusion in addition to standardized perioperative anesthetic and analgesic management. Ketamine will be administered as an intravenous bolus of 0.5 mg/kg followed by a continuous intravenous infusion at 2–5 mcg/kg/min. The infusion will be started before surgical incision and continued throughout the intraoperative period.</i_keyword>
      <i_keyword>Intervention group: Magnesium group. Participants will receive intraoperative magnesium sulfate infusion in addition to standardized perioperative anesthetic and analgesic management. Magnesium sulfate will be administered intravenously at a dose of 40 mg/kg over 15 minutes before induction of anesthesia, followed by a continuous intravenous infusion of 15 mg/kg during the surgical procedure until skin closure.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Acute postoperative pain intensity. Timepoint: 24 hours after surgery. Method of measurement: Numerical Rating Scale from 0 to 10.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Postoperative opioid consumption. Timepoint: Within 24 hours after surgery. Method of measurement: Total opioid dose consumed during the first 24 postoperative hours.</sec_outcome>
      <sec_outcome>Opioid-related side effects and adverse events. Timepoint: Postoperative period. Method of measurement: Nausea, vomiting, hallucinations, agitation, hypotension, bradycardia, and muscle weakness.</sec_outcome>
      <sec_outcome>Pain intensity. Timepoint: 24 hours after surgery. Method of measurement: Numerical Rating Scale from 0 to 10.</sec_outcome>
      <sec_outcome>Time to first rescue analgesia. Timepoint: Postoperative period. Method of measurement: Time from completion of surgery to first request for rescue analgesia.</sec_outcome>
      <sec_outcome>Persistent postoperative pain / chronic pain development. Timepoint: 6 months after surgery. Method of measurement: Assessment of postoperative pain at six months.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Evercare Hospital Lahore</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2025-04-30</approval_date>
        <contact_name>Institutional Research Committee Evercare Hospital Lahore</contact_name>
        <contact_address>D1 Commercial , NECHS Block D 1 Nespak Housing Society Lahore Lahore Punjab Pakistan</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
